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In recent years, increasing attention has been paid to problems of external validity, specifically to methodological ap-
proaches for both quantitative generalizability and transportability of study results. However, most approaches to these
issues have considered external validity separately from internal validity. Here we argue that considering either internal
or external validity in isolationmay be problematic. Further, we argue that a joint measure of the validity of an effect esti-
mate with respect to a specific population of interest may bemore useful: We call this proposedmeasure target validity.
In this work, we introduce and formally define target bias as the total difference between the true causal effect in the tar-
get population and the estimated causal effect in the study sample, and target validity as target bias = 0. We illustrate
this measure with a series of examples and show how this measure may help us to think more clearly about compari-
sons between experimental and nonexperimental research results. Specifically, we show that even perfect internal
validity does not ensure that a causal effect will be unbiased in a specific target population.
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In recent years, increasing attention has been paid to prob-
lems of external validity: both the generalizability of study re-
sults to the population from which the study sample was drawn
and the transportability of results from a study sample to an
external target population (1–12). In either case, a result is exter-
nally valid if the true effect in the study sample is unbiased for
the true effect in the target population. (This usage is formalized
in Web Appendix 1, available at https://academic.oup.com/aje;
it is consistent with that of Shadish et al., who regard external
validity as the question of whether “the causal relationship holds
over variation in persons” (13, p. 472) and other factors, as well
as that of Imbens (11).) In contrast, a result is internally valid
when the effect estimated in the study sample is unbiased for
the true effect in that sample (and not necessarily in some tar-
get population; seeWebAppendix 1).
Both generalizability and transportability can be addressed
by a combination of assumptions and statistical approaches (1, 9).
However, most discussions of external validity to date have con-
sidered external validity separately from questions of internal
validity and have typically been predicated on an assumption
of perfect internal validity. Such an approach can create substan-
tial issues for a public health decision-maker. For example, sup-
pose a decision-maker wants to know whether to intervene in a
particular target population and has 2 sources of information:
1) results from a well-conducted trial of the intervention in a
population that is unlike the target population and 2) results
(possibly still confounded) from awell-conducted observational
study of the intervention in a population that is representative
of the target population. (Here and hereafter, the reader can
take “representative” to mean “a simple random sample of,”
though the reader can consider an expanded usage including
situations in which we have a nonrandom sample of the target
population with known sampling probabilities and we use
those probabilities properly in analysis to weight back to the
target population.)
How should a decision-maker decide on a next step in such
a situation? Conventional approaches would suggest that the
internally valid evidence—in this case, that from the trial—
should be privileged, with only informal attention being paid
to the external validity of those results. In this work, we argue
that such questions are more subtle, and particularly that con-
sidering either internal validity or external validity in isolation
may be problematic. Further, we argue that a joint measure of
the validity of an effect estimate with respect to a specific pop-
ulation of interest (target population), a measure we here call
target validity, may bemore useful.
study, which is seen in the open path from S = 1 (which is
boxed, to indicate that we analyze only those who are in our
study sample) to the outcome Y, [S = 1] ← Z → Y (17, 18). In
addition, regardless of whether or not there is this sort of nonex-
changeability, it is a mathematical certainty that nonnull causal
effects will always exhibit heterogeneity on either the risk dif-
ference scale or the risk ratio scale if the baseline risk of the out-
come changes (seeWebAppendix 2) (19).
In the absence of discussion of the target population, it is typ-
ically implied or assumed that the target population is either
1) exactly the study sample (in which case generalizability is a
nonissue) or 2) the population of which the study sample is a
simple random sample (in which case generalizability is assured
in expectation). In both cases, it is assumed that the target popu-
lation is in some way implicitly defined by the inclusion and
exclusion criteria of the study.
These are questionable assumptions, however. Regarding the
first case noted above, rarely do we desire inference only in the
study sample itself, without any interest in principles generaliz-
able to other groups. Indeed, the idea that no inference is desired
outside of the study sample may be ethically as well as scientifi-
cally problematic: Few human subjects review boards would
approve a randomized trial that actively sought to create knowl-
edge which was of no use beyond the study sample (though we
can imagine this being the case in large-scale pragmatic set-
tings). In addition, if the goal is to take action in the target popu-
lation, then the study sample will always differ from the target
population in time:Wewill only apply the results of the study to
the target population in the future (20, 21).
The second case is likewise questionable. The fact that ran-
domized trials require informed individual consent from study
participants effectively eliminates the possibility of a true simple
random sample from a target population (again, this can some-
times be avoided in pragmatic or community-randomized set-
tings). More importantly, perhaps, randomized trials routinely
overenroll persons at high risk of the outcome under study in
order to enhance precision; for example, human immunodefi-
ciency virus prevention trials will frequently overenroll persons
who report high-risk sexual behavior. Such risk enrichment en-
sures that the study sample is not a simple random sample of
the target population and can easily lead to lack of generaliz-
ability (see Web Appendix 2). Furthermore, it is common for
inclusion and exclusion criteria of a randomized trial to walk a
thin line between ensuring high rates of the outcome of inter-
est and ensuring low rates of adverse events, further increasing
the likelihood that the study sample is not a simple random






Figure 1. Causal diagrams for nonexchangeability for internal valid-
ity due to confounding (A) and nonexchangeability for external validity
due to sampling bias (B).
In this paper, we first discuss the necessity of a target popula-
tion to inference and decision-making and the near-certainty that 
causal effects derived from classical randomized clinical trials 
cannot be unconditionally generalized to arbitrary target popula-
tions when studying humans or other complex animals. We 
define target validity and illustrate the measure with an exam-
ple. We conclude with discussion of the implications of a target 
validity approach to causal inference for attempts to describe a 
“hierarchy” of study designs.
For convenience and conceptual clarity, we initially concen-
trate on randomized studies. This is because it is widely under-
stood that an intent-to-treat analysis of a randomized clinical trial 
(with perfect measurement and no missing data, including no 
loss to follow-up) will yield an internally valid estimate of the 
causal effect of treatment (or intervention) assignment. Addi-
tionally, under perfect adherence, this will also be an estimate 
of the effect of the treatment itself. We later expand to discuss 
observational studies as well, where internal validity is not 
guaranteed. We also focus primarily on the problem of gener-
alizability (and not transportability) to simplify our discussion; 
again, in a generalizability framework, the study sample is a 
proper subset of the target population, whereas in transportability 
the study sample is at least partially external to the target popula-
tion (1, 9). While superficially similar, current methods address 
these 2 problems separately; in particular, presently only gener-
alizability can be addressed using familiar causal diagrams 
(14), while transportability requires a somewhat different graphi-
cal approach (7). We consider differences between these con-
cepts further in the Discussion section.
TARGET POPULATIONS AND EXTERNAL VALIDITY
It is near-universally overlooked that estimates of causal effects 
obtained from a study sample are only well-defined if they include 
specific reference to a target population in which they are said 
to apply (15). Indeed, in few, if any, studies—randomized trials 
or otherwise—do authors report the target population for their 
causal effect, much less attempt to generalize quantitatively to 
that target. As an illustration, we reviewed all randomized trials 
published in the New England Journal of Medicine between 
January 1, 2016, and December 31, 2016, and found that only 1 
in 5 (21%) of these papers discussed generalizability or external 
validity concerns in describing the results; of those that did 
mention such issues, relatively few described statistical issues 
related to generalizability, and none attempted to standardize 
trial results to a target population (16).
Why is external validity a problem? When a study sample is 
not formally representative of (or alternately, the same as) the 
target population, we cannot assume that the true causal effect 
in a study sample will be the same as the true effect in the popu-
lation, and thus that the (even unbiased) estimate of the study 
sample effect will also be an accurate estimate of the target pop-
ulation effect. Differences in these effects may occur for 2 main 
reasons: nonexchangeability or mathematical necessity. Nonex-
changeability for generalizability (in particular) can be thought 
of as a strong analogy to confounding, and it can be illustrated 
using causal diagrams (17). Figure 1A shows confounding of 
the effect of X on Y due to Z through the open path X ← Z → Y; 
Figure 1B shows nonexchangeability due to sampling into the
Irrespective of ongoing debates on the value of representa-
tiveness (23–27), it is rare for the study sample in a random-
ized trial to actually be representative of the target population.
When the sample is nonrepresentative of a target population,
claims of external validity in that target population cannot be
made without assumptions about similarities between the study
sample and the target population or about homogeneity of
effects.
In addition, even if a study sample is sampled at random from
the target population of interest, it will not be representative of
other target populations. For example, consider a randomized
trial for which the investigators’ target population is all residents
of North Carolina. If the trial is conducted in a randomly selected
subgroup of North Carolina residents, it might be representative
of (and thus externally valid for) the state of North Carolina—but
we would have no such guarantees for the United States as a
whole (or the state of South Carolina, though that is a problem
of transportability rather than generalizability). Because of this,
to claim generally that a trial has “good external validity” is a
category error: Since the prevalence of effect-measure modi-
fiers differs from one target population to another, the degree
to which a causal effect estimate from a randomized trial is
externally valid will (in general) differ from one target popu-
lation to another as well (9). For example, if biological sex is
an effect-measure modifier and a randomized trial population
is composed of 75% women, the generalizability of the re-
sults will differ between 3 target populations containing 75%,
50%, and 25%women, respectively. If external validity changes
depending on the choice of target population, then any claim of
“external validity” or “generalizability” which does not specify
the target population is not a meaningful scientific claim. Ulti-
mately, it is useful to remember that generalizability is a relation-
ship between a study sample and a target population for a
particular question—rather than a single inherent characteris-
tic of a study (1).
IDENTIFICATIONOF EXTERNALLY VALID EFFECTS IN A
TARGET POPULATION
Pearl, Bareinboim, and others give conditions for both gener-
alizability and transportability (1, 3, 5, 7), key among them being
independence (conditional or otherwise) of study participation
(or sampling) from the outcome under study. In generalizability,
this can be seen as a missing-data problem under complete-case
analysis, in which the outcomes in the target population aremiss-
ing except in the study sample (18). It may often be more intui-
tive (though less formal) to think of generalizability in terms of
effect-measure heterogeneity: If there is an effect-measure
modifier of a causal effect that has a different prevalence in
the study sample than in the target population, generalizabil-
ity from the study sample to the target population is not guaran-
teed (seeWebAppendix 2) (16, 28).
If all such effect-measure modifiers are measured in the ran-
domized trial and the target population, then (under additional
assumptions or conditions, often including external positivity
(1), external consistency (5), and external interference equiva-
lence (5)) it is possible to analytically generalize a causal effect
from a study sample to a specific target population (9, 16). As
with confounding, the possibility of unmeasured effect-measure
modifiers’ leading to nonexchangeability between the study sam-
ple and the target population is a potential issue. As noted
above, this issue can be solved in expectation with random sam-
pling of study participants from a target population. In the absence
of such random sampling, we can assert generalizability to a spe-
cific target population only under an assumption similar to the
typical “no unmeasured confounding” assumption in observa-
tional studies (1). (Recently developed methods provide an
analysis of sensitivity of target population effect estimates
to unobserved effect-measure modification (29).)
Few population health scientists would accept the assertion—
implicit or explicit—that the crude (unadjusted) results of an
observational study were valid without attention to any possible
confounding, but population health science has paid less atten-
tion to the highly analogous claim that the results of a random-
ized trial are immediately, or crudely, generalizable to a particular
target population. The latter claim is neither more nor less valid
than the former: Both depend on an assumption of exchangeabil-
ity. An exposure-outcome relationship in the presence of unexam-
ined, possibly uncontrolled confounding is not considered more
than an association: This is uncontroversial. We suggest that
a result from a randomized trial in the presence of unexam-
ined nongeneralizability—while interpretable as a causal effect
in the study sample—should likewise be considered merely an
“association” with respect to estimation of the causal parame-
ter in the target population. That is, while the result of a ran-
domized trial is indeed a valid estimate of a causal effect in the
study sample, the potential for nonexchangeability with the tar-
get populations should give us pause before we interpret the
effect as a valid estimate of the causal effect in the target popu-
lation (30).
TOWARD TARGETVALIDITY
Above, we discussed the idea that results that are identified as
“internally valid” are not as useful (or as complete) as sometimes
thought, because no causal effect estimate is well-specified with-
out a target population, and the study sample is rarely if ever
equal to, and often is not representative of, the target popula-
tion.We also noted that a simple and unelaborated claim that a
result is “externally valid” (without reference to a specific and
well-characterized target population) was poorly formed as a
scientific statement. In sum, then, it makes little sense to speak
of internal validity in isolation, and it makes little sense to
speak of external validity in the abstract.
How then ought we discuss the validity of our studies? Here,
we suggest that public health and medicine may benefit from a
more integrated perspective than what is promoted by the current
separation of internal and external validity. We suggest a com-
bined metric that addresses the total validity of a causal effect
estimate in the specified target population, a quantity we call
“target validity.”
This concept extends the framework presented by Imai
et al. (30), which decomposed the overall bias in a treatment
effect estimate for a well-defined target population into internal
and external components. Those authors showed that the bias
present when one is using a sample of treated and control sub-
jects to estimate the average causal effect in a target population
can be decomposed into 4 pieces: internal validity bias due to
target population of interest. This idea, while simple, has poten-
tially significant implications for the way we generate and
evaluate evidence. Several points are worth discussing.
We argue that the hierarchy in which internal validity is of pri-
mary importance to overall validity and external validity is con-
sidered only secondarily, while sometimes a useful perspective,
may also be misleading. While is it true that, lacking inter-
nal validity, perfect external validity (or perfect representa-
tiveness of the target population) will not help an investigator
obtain an estimate of effect that is unbiased with respect to the
target population, it is equally true that even with perfect inter-
nal validity, a lack of external validity leads to bias with respect
to the target population (WebAppendix 3, example b). Integrat-
ing our thinking about internal and external validity to a greater
degree may be more useful in improving our approach to causal
effect estimation.
Once we accept that validity should be measured with respect
to a specific target population, the symmetry of internal and
external validity becomes apparent: Internal validity can be threat-
ened by confounding and selection bias, which can be dealt with
by randomizing treatment. External validity, in a similar way,
can be threatened by lack of exchangeability between the study
sample and the target population, which can be dealt with by
random sampling from the target population into the study. In
both cases we can still sometimes (though not always (17, 32))
obtain valid results through quantitative adjustment for con-
founding factors and selection bias (internal validity) or for causal
pathways linking sampling into the study and the outcome (exter-
nal validity)—if we have correctly chosen, measured, and mod-
eled the variables for whichwe need to account.
It may alarm some scientists (and perhaps some policy-
makers) to confront quantitatively the idea that—unless a
study population is randomly sampled from the target popu-
lation of interest (or sampled with known probabilities and
then reweighted)—randomization of treatment alone does
not guarantee an unbiased estimate of effect in the target
population (as we illustrate in Web Appendix 3, example
c). Indeed, the idea that the result of a randomized trial will
be valid in the target population rests on the same kind of
(potentially invalid) assumptions as those in any observa-
tional analysis. It follows from all of the above that the gold
standard of evidence for assessing a causal effect estimate
in a given target population is not simply a randomized trial
but rather a randomized trial conducted among a random
sample of the target population.
Table 1. Relationships Between RandomSampling/Treatment Assignments and Internal and External Validitya
Is the Treatment
Randomized or Observed?
Is the Study Sample Representative of the Target?
Internal Validity
Representative Not Representative
Randomized Web Appendix 3, example a Web Appendix 3, example b High internal validity
Observed Web Appendix 3, example c Web Appendix 3, example d Unknown internal validity
External validity High external validity Unknown external validity
a Interior cells refer to numerical examples fromWeb Appendices 3 and 4. Representativeness of the study sample
may be achieved most simply through random sampling of the study sample from the target population; it may also
arguably be achieved by sampling of the study sample from the target population with known sampling proportions
and then applying those weights correctly during analysis.
1) observed and 2) unobserved factors and external validity 
bias due to 3) observed and 4) unobserved factors. As they docu-
mented in their paper (30), different study designs have different 
trade-offs in terms of these 4 components. For example, a “typi-
cal” nonrepresentative randomized trial may have (in expecta-
tion) higher internal validity because randomization provides 
exchangeability between study arms in expectation, but lower 
external validity for the target population of interest. In con-
trast, a “typical” nonexperimental study conducted in a large-
scale data set may have lower internal validity (especially due 
to unobserved confounders) but larger external validity.
Starting with these ideas, we give a formal definition (in terms 
of potential outcomes) of target validity for the risk difference in 
Web Appendix 1 for both the generalizability and transportability 
cases. Here, we informally note that target bias for the risk differ-
ence is simply the sum of internal bias and external bias for a spe-
cific target population, and can be thought of therefore as the 
difference between the true causal risk difference in the target 
population and the estimated risk difference in the study sample. 
We illustrate the utility of the target validity concept in Web 
Appendix 3 with an example, in several parts; data for this exam-
ple are given in an accompanying Excel (Microsoft Corporation, 
Redmond, Washington) spreadsheet (Web Appendix 4).
The example from Web Appendix 3 helps us fill out a 2 × 2 
table to guide our understanding of target validity, addressing 2 
questions: First, is the study sample representative of the target 
population (the columns)? And second, is the treatment ran-
domized or observed (the rows)? We offer such a 2 × 2 table  as  
Table 1. In this table, the top-left cell represents a doubly ran-
domized experiment (31), while the contents of the cells corre-
spond to examples a–d in Web Appendix 3. Changing our 
orientation to target validity helps us recognize that only when a 
study sample is representative of the target (randomly sampled 
from the target; alternately, sampled from the target with known 
sampling proportions and then weighted properly to represent 
the target) and treatment is randomized in the study sample can 
we count on high validity with respect to the target population 
(Web Appendix 3, example a)—in all other situations (Web 
Appendix 3, examples b–d), the balance of internal and exter-
nal validity is a priori unknown.
DISCUSSION
Here we have introduced the concept of target validity, as 
the overall validity of a causal effect estimate in the specific
This, in turn, puts in question the many rankings of evidence—
hierarchies of study designs—that near-universally place ran-
domized trials above observational studies. Such rankings
seem to us likely to be based on one of 3 points: 1) a belief that
the target population is equal to, or perfectly represented by,
the study sample; 2) a belief that internal validity alone is a
proper basis for decision-making or scientific evidence (possi-
bly related to underlying beliefs that randomized trials
uncover scientific truths or laws about the universe, a belief that
seemingly discounts the possibility of effect heterogeneity); or
3) a belief that randomized trials have greater target validity
(in general) than observational studies (a counterpoint to which
was given above). Regardless of underlying motivation, the
fact of such hierarchies is questionable: Specifically, given a
choice between an observational but possibly confounded esti-
mate and a randomized but poorly generalizable estimate, it
does not seem obvious which should inform public health or
clinical decision-making to a greater degree.
In this work we have focused on generalizability (in which
the study sample is a subset of the target population) rather than
transportability (the study sample is not a subset of the target
population). In Web Appendix 1, we derive a formal definition
of target bias and thus target validity for transportability; but
here we wish to draw the reader’s attention to 2 key differences
between generalizability and transportability. First, at present,
problems of transportability cannot be expressed using causal
diagrams but require (similar, but not identical) selection dia-
grams instead (7). Thus, direct graphical analogies of transport-
ability to generalizability should proceed cautiously. Second,
we argued above that the only way to guarantee external valid-
ity in expectation is to randomly select the study sample from
the target population. In the transportability case—in which the
study sample is not a subset of the target population—such
sampling is simply not possible, and thus analytical approaches
are probably necessary.
Wemention several additional points briefly. First, some study
designs, including pragmatic and community-randomized trials
and certain pseudoexperiments and nonexperimental studies,
may have extremely high target validity under some circum-
stances and are attractive study designs in part for exactly that
reason.Morework is needed to characterize the conditions under
which target validity is high and exactly what data are required
when quantitative approaches to generalizability or transportabil-
ity are to be pursued (9, 16), as well as power calculations for
such analyses. Second, consideration of target validity may
have applications to the way we conduct and consider meta-
analyses, especially meta-analyses of observational studies
(33). We should first ask, what is the target population of
each study in the meta-analysis? And then, what is the final
target population for the result of the meta-analysis? Third,
we have assumed throughout this work that the target popula-
tion is broadly relevant to the intervention under study; clearly,
a smoking cessation intervention is unlikely to prevent mortal-
ity in a population of nonsmokers. Thus, the role of common-
sense contextual information should not be overlooked. Fourth,
investigators may wish to estimate effects only for a subset of a
study sample, as in the effect of the treatment in the treated; but
the external validity of those effects must be evaluated just as
for sample average causal effects.
Finally, it is possible that the components of target validity are
not of equal importance: Perhaps (consistent with widely held
views) internal validity is more important than external validity
inmany or evenmost real-world cases. Thismight be particularly
true if issues of internal validity, such as confounding or selec-
tion bias, lead to reversal of sign (e.g., make a harmful treatment
look helpful) more often than external validity. Evidence on
whether internal validity is more important than external valid-
ity in real-world settings would be welcome, but such broad
empirical investigation of this issue is beyond the scope of
the present work.
In conclusion, we propose that the prioritization of inter-
nal validity over external validity, and the related consideration
of internal validity and external validity separately, is a perspec-
tive that has weakened, rather than strengthened, public health
evidence writ large. We encourage other investigators to gener-
alize their thinking about validity and study hierarchies and to
embrace the idea of target validity.
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